FINWIRES · TerminalLIVE
FINWIRES

上海復旦微電子2026年第一季獲利成長9%

By

-- 根據週三提交給香港交易所的文件顯示,上海復旦微電子(港交所代碼:1385,滬交所代碼:688385)2026年第一季實現淨利潤1.483億元人民幣,較上年同期的1.362億元人民幣增長9%。 這家積體電路製造商的港股週四午後交易下跌近8%。 每股收益為0.18元人民幣,高於去年同期的0.17元。 數據顯示,營收年增16%至10.3億元。

Related Articles

Equities

Berenberg Adjusts Estimates for Galp Energia After 'Solid' Q1 Results; Hold Rating Maintained

Berenberg updated its earnings forecasts for Galp Energia (GALP.LS) after the Portuguese energy company reported its first-quarter results."Galp reported a solid set of results for Q126 on 27 April from an operational point of view, and beat consensus EBITDA expectations, although this was offset by some cash flow adjustments in the period. Delivery of the important Bacalhau project (Brazil) appears to be ahead of expectations, and, after a strong Q1 in the refining business, Galp is moving towards confirming the terms of its downstream merger with Moeve. In the earnings call, the company indicated that its 2026 guidance is now likely out of date given the macro backdrop, and that it may update its FY26 outlook in the Q2 results. We leave our Hold rating and EUR20 price target unchanged," the research firm said Wednesday.Against this backdrop, the research firm increased its 2026 EBITDA assumption by 3%, while cutting its cash flow from operations and free cash flow estimates by 4% and 3%, respectively, to account for a recent 320 million-euro renewable acquisition and other liquidity adjustments.Meanwhile, analysts maintained their share repurchase projection for 2026 at 250 million euros, while boosting their 2027 forecast to 455 million euros, which is 10% above consensus. Berenberg's EPS estimates for 2026 through 2028 were also revised upwards.

$GALP.LS
Asia

Henlius Biotech Doses First Patient in Lung Cancer Drug Trial in China

Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 1 clinical study of HLX3901 in mainland China, according to a Thursday Hong Kong bourse filing.The drug is being tested for the treatment of patients with advanced small-cell lung cancer or neuroendocrine carcinoma.

$HKG:2696
Equities

BP Confirms Preliminary Offshore Exploration Agreement With Venezuela

BP (BP.L) entered into a memorandum of understanding with the Bolivarian Republic of Venezuela to establish "potential areas for co‑operation in material offshore gas and future exploration," according to a statement sent toon Thursday.Venezuela's Acting President Delcy Rodríguez announced in a Wednesday signing event its offshore natural gas exploration deal with the British oil major, which covers the Deltana Platform, an oil and natural gas reservoir in the nation's eastern waters, according to a same-day report from Bloomberg News.BP Executive Vice President William Lin also said the company plans to launch a permanent regional office in Caracas, Venezuela.

$BP.L